BAXTER INTERNATIONAL INC
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $BAX in the last 30 days.
See all $BAX insider activity →Baxter International recalled two lots of 0.9% Sodium Chloride Injection IV saline due to fibreglass contamination, posing risks of blood clots and death. The recall affects 14 US states and was announced on 25 August 2026. The FDA classified it as a voluntary recall, and Baxter is contacting affected customers for returns.
Baxter International recalled two lots of 0.9% sodium chloride injections due to potential fiberglass contamination. The solution is used in hemodialysis and was distributed to 14 U.S. states. No injuries or illnesses have been reported, according to the company.
Baxter International is recalling one lot of 70% Dextrose Injection due to stainless steel particles found in the solution. The affected lot, Y495066, was distributed to healthcare providers in select states, including Alabama, Georgia, and Tennessee. The company has not reported any adverse events. Patients using parenteral nutrition should contact their compounding pharmacy for guidance. This is the third IV product recall in recent weeks, according to the FDA.
Over the past 7 days, alphai's AI scored 7 news stories mentioning BAX (BAXTER INTERNATIONAL INC). Coverage has skewed bearish: 0 bullish, 5 neutral, and 2 bearish.
Recent BAX coverage spans corporate actions, financial news and market movers.
Potential negative impact on Baxter's stock as hospitals halt use of recalled saline.
Recall may pressure Baxter's stock as hospitals seek alternatives.
Recall may cause short-term sales disruption and heightened scrutiny of Baxter's IV product line.
Potential reputational risk and possible future costs; no immediate operational impact reported.
Potential reputational risk and possible future regulatory scrutiny; no immediate financial impact disclosed.
alphai scores every news story that mentions BAX with an AI model for sentiment and relevance, and aggregates insider trades from BAXTER INTERNATIONAL INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Baxter International recalled two lots of 0.9% Sodium Chloride Injection IV saline due to fibreglass contamination, posing risks of blood clots and death. The recall affects 14 US states and was announced on 25 August 2026. The FDA classified it as a voluntary recall, and Baxter is contacting affected customers for returns.
2 min readBaxter International recalled two lots of 0.9% sodium chloride injections due to potential fiberglass contamination. The solution is used in hemodialysis and was distributed to 14 U.S. states. No injuries or illnesses have been reported, according to the company.
1 min readBaxter International is recalling one lot of 70% Dextrose Injection due to stainless steel particles found in the solution. The affected lot, Y495066, was distributed to healthcare providers in select states, including Alabama, Georgia, and Tennessee. The company has not reported any adverse events. Patients using parenteral nutrition should contact their compounding pharmacy for guidance. This is the third IV product recall in recent weeks, according to the FDA.
3 min readShinyHunters claims to have leaked 7.1 million Salesforce records from Baxter International, including personal data. Baxter acknowledged unauthorized activity but denied impact on operations. The company expects no material financial or operational impact. Baxter reported $11.24 billion in net sales for 2025.
2 min readShinyHunters claims to have leaked 7.1 million Salesforce records from Baxter International, including personal data. Baxter acknowledged unauthorized activity but denied any operational impact. The company expects no material financial or operational effects. Baxter reported $11.24 billion in net sales for 2025.
2 min readCFO turnover at Fortune 500 and S&P 500 companies is projected to reach 18.3% in 2026, the highest since 2020. Key CFO changes include AT&T, Caterpillar, Oracle, Nike, and Pfizer. The average age of new CFOs is projected to be 48, down from 52 in 2025. Notable appointments include GE HealthCare, Baxter International, and Ameresco.
5 min readCentene's CFO Drew Asher to step down by year-end, succeeded by Chris Neczypor. Baxter International names John Rogers as CFO. GE HealthCare appoints William K. Grogan as CFO. QVC Group's CEO David Rawlinson steps down, Mike George takes interim role. Changes impact leadership at Fortune 500 companies.
3 min readBaxter International (BAX) has named John Rogers as its new CFO, effective October 2026. Rogers succeeds Joel Grade and brings extensive finance experience from Smith+Nephew and WPP. CEO Andrew Hider highlights Rogers' global finance expertise and leadership style. Baxter is a global medical technology company with a diverse healthcare product portfolio.
2 min readJohn Rogers, CFO of Smith+Nephew (LON: SN, NYSE: SNN), will leave to become EVP and CFO at Baxter in October. Smith+Nephew reported $1.6B in Q2 revenue and reduced its full-year growth forecast to 4%. The company has initiated a search for Rogers' successor, with Pierre Palassian serving as interim CFO.
2 min readBAXTER INTERNATIONAL INC (BAX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 FOR IMMEDIATE RELEASE BAXTER APPOINTS JOHN ROGERS CHIEF FINANCIAL OFFICER Global medtech CFO with broad transformation and leadership experience to help advance Baxter’s turnaround, financial discipline and value creation DEERFIELD, Ill., AUGUST 19, 2026 – Baxter Int
2 min read
